TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07016321: Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)

Sponsor: Johns Hopkins University · Phase: PHASE2/PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 600 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$11,477,760

Rescue Site Savings

+$7,568,148

Unlock Full NCT07016321 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07016321 Rescue Dossier →